MedTrace Logo

Assessment of HyperQ Signal for Detecting Ischemia During Dobutamine Stress ECG

NCT00310622 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2007-03-01

No results posted yet for this study

Summary

The purpose of the study is to verify the ability of the HyperQ signal to detect Dobutamine induced Ischemia. The gold standard for ischemia will be the results of Angiography if performed, or Echocardiographic imaging, which was performed during the test.

Conditions

  • Myocardial Ischemia

Interventions

DEVICE

HyperQ Signal recording

Sponsors & Collaborators

  • BSP Biological Signal Processing Ltd.

    lead INDUSTRY

Principal Investigators

  • David Rosenmann, MD · Shaarey Zedek Hospital, Jerusalem, Israel

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2007-02-28

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310622 on ClinicalTrials.gov